Sarepta Therapeutics crashed 64% today after the Food and Drug Administration chose not to accept the company's request for accelerated approval of its Duchenne muscular dystrophy drug eteplirsen. Sarepta had hoped to get ahead of competitors Prosensa and GlaxoSmithKline and bring a treatment for the fatal disease to market first, but the FDA argued that Sarepta's phase 2 trials didn't involve a large enough sample size to warrant approval without a phase 3 study. That will push out Sarepta's timeline dramatically, potentially giving its competitors a chance to catch up.********** I would love to know what is going on right now but I will bet all have been in talks. Very Exciting. I am going to buy more SRPT.